Partnering
Partnerships are an important component of our business plan. We have developed valuable relationships with world-class biotechnology and biopharmaceutical companies and have established research collaborations with distinguished academic investigators. Contact us today to learn more about our clinical programs or to find out how we can help you succeed with your antibody selection.
Clinical Collaboration Partner: Merck
Clinical evaluation of the safety and effectiveness of pepinemab in combination with pembroblizumab (anti-PD-1) for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck (HNSCC).
ClinicalTrials.gov Identifier: NCT04815720
Clinical Collaboration Partner: Alzheimer’s Association
Vaccinex received a $750,000 grant from the Alzheimer’s Association under the 2020 Part the Cloud Program to evaluate its lead drug candidate, pepinemab, in Alzheimer’s Disease (AD).
Link to press release
Clinical Collaboration Partner: Alzheimer’s Drug Discovery Foundation
Vaccinex received an investment of up to approximately $3 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to evaluate pepinemab in Alzheimer’s Disease (AD).
Link to press release
Clinical Collaboration Partner: Merck KGaA, Darmstadt, Germany
Clinical evaluation of the safety and effectiveness of pepinemab (VX15/2503) in combination with avelumab (anti-PD-L1) in the treatment of advanced non-Small Cell Lung Cancer (NSCLC).
ClinicalTrials.gov Identifier: NCT03268057
Collaboration Partner: Emory University
Clinical Evaluation of VX15 in combination with immune checkpoint inhibitors in neoadjuvant biomarker trials in oncology.
ClinicalTrials.gov Identifier: NCT03690986 (Resectable Head and Neck Cancer)
ClinicalTrials.gov Identifier: NCT03769155 (Resectable Melanoma)
Clinical Collaboration Partner: University of Rochester
Clinical Evaluation of pepinemab (VX15/2503) in combination with pepinemab and avelumab after folfirinox for patients with metastatic pancreatic adenocarcinoma.
ClinicalTrials.gov Identifier: NCT05102721
ActivMab Collaboration Partner: Catalent Pharma Solutions
Research collaboration with Catalent for the creation of novel anti-cancer agents.
ActivMab Collaboration Partner: Surface Oncology, Inc.
Research collaboration with Surface Oncology for discovery and selection of monoclonal antibodies to oncology targets.
Link to press release
Preclinical Collaboration Partner: NIH-NCI
Preclinical evaluation of VX15 in Head and Neck Cancer.
Link to publication
Preclinical Collaboration Partner: University of Sydney, The Children’s Hospital at Westmead
Preclinical evaluation of anti-SEMA4D antibodies in a preclinical model of Rett Syndrome
Link to publication
Preclinical Collaboration Partner: University of British Columbia and separately University of Central Florida
Preclinical evaluation of anti-SEMA4D in Huntington’s Disease
Link to publication